Latest News

The prognostic value of circulating tumor cells (CTCs) in patients with hormone-naïve oligometastatic prostate cancer (HNoMPC) undergoing cytoreductive radical prostatectomy (CRP) is unknown. To determine the pre- and postoperative prognostic value of CTC enumeration in patients undergoing CRP. Thirty-three patients with HNoMPC from the prospective, single-arm ProMPT trial who underwent CRP between 2014 and 2015 […]

To examine trends in online search behaviors related to prostate cancer on a national and regional scale using a dominant major search engine. Google Trends was queried using the terms “prostate cancer”, “prostate specific antigen” (PSA), and “prostate biopsy” between January 2004 and January 2019. Search volume index (SVI), a measure of relative search volume […]

The use of multiparametric magnetic resonance imaging (mpMRI) to assess prostate cancer (PCa) has increased over the past decade. We aimed to assess if preoperative mpMRI lesion score, a variable routinely available for men undergoing pre-biopsy MRI, improves the performance of commonly used preoperative predictive models for PCa recurrence. We analyzed data from 372 patients […]

Active surveillance (AS) and radical prostatectomy (RP) are both accepted treatments for men with favorable-risk localized prostate cancer (PCa) (ie, clinical tumor category 1-2b, Gleason Grade Group 1-2, and prostate-specific antigen < 20 ng/mL). However, head-to-head studies comparing oncologic outcomes and survival between these 2 treatment strategies are warranted. The objective of this study was to […]

Genomic characterization of prostate cancer (PCa) biopsies may improve criteria for the selection of patients suitable for active surveillance (AS). To identify somatic genomic aberrations associated with adverse outcome as AS protocol exclusion indicators. Whole-exome sequencing profiles were generated for Gleason score (GS)=3+3 biopsies obtained from 54 PCa patients enrolled in two AS protocols. Patients […]

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a disease of chronic pain and its characteristics can be diverse. Patients with IC/BPS are categorized into 2 types based on their dominant symptoms: those with bladder-associated symptoms and those with other pelvic-organ symptoms. In addition, other chronic pain conditions, such as fibromyalgia and irritable bowel syndrome, often coexist […]

Several large prospective studies have shown that active surveillance (AS) is an effective strategy to postpone or even prevent radical treatment and its associated morbidity in patients diagnosed with prostate cancer, without compromising disease prognosis.1-3 However, these studies all use strict inclusion criteria and thus mainly describe outcomes of patients with (very) low-risk disease. A […]

San Francisco, CA (UroToday.com) — World Trade Center responders with prostate cancer showed signs that inflammation was activated in the prostate after exposure to dust from the World Trade Center site, possibly causing chronic inflammation that contributed to their cancer, according to a study by Mount Sinai researchers in Molecular Cancer Research in June. Inflammation has long […]

{{header-clinical-trials-navigation}} SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor Condition: Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03992131 Sponsor: Clovis Oncology, […]

To assess the impact of pretreatment hemoglobin (Hb) and body mass index (BMI) on overall survival (OS) following radical cystectomy (RC) for bladder cancer (BCa) in males versus females. We retrospectively reviewed 152 patients treated with RC for BCa between 2012 and 2016. Hb was categorized as low Hb or high Hb. BMI was classified […]